Risk Factors for Ebola Exposure in Health Care Workers in Boende, Tshuapa Province, Democratic Republic of the Congo.
Democratic Republic of the Congo
Ebola
health care workers
risk factors
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
04 09 2022
04 09 2022
Historique:
received:
17
08
2020
accepted:
30
11
2020
pubmed:
4
12
2020
medline:
9
9
2022
entrez:
3
12
2020
Statut:
ppublish
Résumé
Health care workers (HCW) are more likely to be exposed to Ebola virus (EBOV) during an outbreak compared to people in the general population due to close physical contact with patients and potential exposure to infectious fluids. However, not all will fall ill. Despite evidence of subclinical and paucisymptomatic Ebola virus disease (EVD), prevalence and associated risk factors remain unknown. We conducted a serosurvey among HCW in Boende, Tshuapa Province, Democratic Republic of Congo. Human anti-EBOV glycoprotein IgG titers were measured using a commercially available ELISA kit. We assessed associations between anti-EBOV IgG seroreactivity, defined as ≥2.5 units/mL, and risk factors using univariable and multivariable logistic regression. Sensitivity analyses explored a more conservative cutoff, >5 units/mL. Overall, 22.5% of HCWs were seroreactive for EBOV. In multivariable analyses, using any form of personal protective equipment when interacting with a confirmed, probable, or suspect EVD case was negatively associated with seroreactivity (adjusted odds ratio, 0.23; 95% confidence interval, .07-.73). Our results suggest high exposure to EBOV among HCWs and provide additional evidence for asymptomatic or minimally symptomatic EVD. Further studies should be conducted to determine the probability of onward transmission and if seroreactivity is associated with immunity.
Sections du résumé
BACKGROUND
Health care workers (HCW) are more likely to be exposed to Ebola virus (EBOV) during an outbreak compared to people in the general population due to close physical contact with patients and potential exposure to infectious fluids. However, not all will fall ill. Despite evidence of subclinical and paucisymptomatic Ebola virus disease (EVD), prevalence and associated risk factors remain unknown.
METHODS
We conducted a serosurvey among HCW in Boende, Tshuapa Province, Democratic Republic of Congo. Human anti-EBOV glycoprotein IgG titers were measured using a commercially available ELISA kit. We assessed associations between anti-EBOV IgG seroreactivity, defined as ≥2.5 units/mL, and risk factors using univariable and multivariable logistic regression. Sensitivity analyses explored a more conservative cutoff, >5 units/mL.
RESULTS
Overall, 22.5% of HCWs were seroreactive for EBOV. In multivariable analyses, using any form of personal protective equipment when interacting with a confirmed, probable, or suspect EVD case was negatively associated with seroreactivity (adjusted odds ratio, 0.23; 95% confidence interval, .07-.73).
DISCUSSION
Our results suggest high exposure to EBOV among HCWs and provide additional evidence for asymptomatic or minimally symptomatic EVD. Further studies should be conducted to determine the probability of onward transmission and if seroreactivity is associated with immunity.
Identifiants
pubmed: 33269402
pii: 6017484
doi: 10.1093/infdis/jiaa747
pmc: PMC9441197
doi:
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
608-615Subventions
Organisme : FIC NIH HHS
ID : D43 TW009343
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Virol Methods. 2018 May;255:84-90
pubmed: 29481881
Emerg Infect Dis. 2010 Jul;16(7):1087-92
pubmed: 20587179
Ann Intern Med. 2014 Nov 18;161(10):753-4
pubmed: 25155746
J Infect Dis. 1999 Feb;179 Suppl 1:S102-7
pubmed: 9988172
J Infect Dis. 2019 Jan 29;219(4):517-525
pubmed: 30239838
Emerg Infect Dis. 2019 May;25(5):911-918
pubmed: 31002071
Sci Data. 2017 Jan 31;4:160133
pubmed: 28140390
BMC Infect Dis. 2015 Oct 13;15:416
pubmed: 26464285
Lancet. 2014 Oct 25;384(9953):1499-500
pubmed: 25390569
N Engl J Med. 2014 Nov 27;371(22):2083-91
pubmed: 25317743
Microbes Infect. 2000 Jan;2(1):39-44
pubmed: 10717539
BMJ Glob Health. 2019 Jul 3;4(4):e001529
pubmed: 31354973
N Engl J Med. 2020 May 7;382(19):1832-1842
pubmed: 32441897
J Infect Dis. 1999 Feb;179 Suppl 1:S87-91
pubmed: 9988169
BMC Infect Dis. 2016 Jun 10;16:263
pubmed: 27286990
J Infect Dis. 2018 Jan 4;217(2):223-231
pubmed: 29253164
J Gen Virol. 2016 Dec;97(12):3120-3130
pubmed: 27902321
Elife. 2015 Nov 03;4:
pubmed: 26525597
Cult Health Sex. 2013;15(4):450-65
pubmed: 23414116
Bull World Health Organ. 1978;56(2):271-93
pubmed: 307456
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
N Engl J Med. 2014 Oct 9;371(15):1418-25
pubmed: 24738640
J Infect Dis. 1999 Feb;179 Suppl 1:S98-101
pubmed: 9988171
J Infect Dis. 2018 Jan 30;217(4):529-537
pubmed: 29329455
PLoS Negl Trop Dis. 2015 Jun 05;9(6):e0003833
pubmed: 26047124
Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):115-23
pubmed: 22754064
Nat Rev Dis Primers. 2020 Feb 20;6(1):13
pubmed: 32080199
Clin Infect Dis. 2016 May 15;62(10):1277-1286
pubmed: 26932131
J Community Health. 2018 Feb;43(1):157-163
pubmed: 28681282
PLoS Negl Trop Dis. 2016 Nov 15;10(11):e0005087
pubmed: 27846221
Nat Commun. 2019 Oct 15;10(1):4531
pubmed: 31615986
Lancet. 2000 Jun 24;355(9222):2210-5
pubmed: 10881895
mBio. 2015 Feb 19;6(2):e00137
pubmed: 25698835
Trop Med Int Health. 2015 Apr;20(4):448-54
pubmed: 25565430
MMWR Morb Mortal Wkly Rep. 2014 Nov 21;63(46):1077-81
pubmed: 25412067
Pan Afr Med J. 2015 Oct 10;22 Suppl 1:9
pubmed: 26779300
Ecohealth. 2017 Sep;14(3):552-563
pubmed: 28831639
J Infect Dis. 1999 Feb;179 Suppl 1:S259-62
pubmed: 9988192